We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.21%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$290M
AUM Growth
+$16.2M
Cap. Flow
-$4.34M
Cap. Flow %
-1.5%
Top 10 Hldgs %
25.51%
Holding
174
New
37
Increased
46
Reduced
48
Closed
32

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$3.3M
2
GEV icon
GE Vernova
GEV
+$2.82M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$2.76M
4
DYN icon
Dyne Therapeutics
DYN
+$2.61M
5
AMZN icon
Amazon
AMZN
+$2.59M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$6M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$4.02M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$3.97M
4
MRUS
Merus
MRUS
+$2.23M
5
META icon
Meta Platforms (Facebook)
META
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 46.45%
2 Technology 15.69%
3 Consumer Discretionary 9.1%
4 Industrials 4.98%
5 Financials 4.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
76
Corbus Pharmaceuticals
CRBP
$184M
$1.55M 0.54%
75,292
+36,499
+94% +$1.87M
AVGO icon
77
Broadcom
AVGO
$1.98T
$1.54M 0.53%
+8,900
New +$1.43M
TEVA icon
78
Teva Pharmaceuticals
TEVA
$42.5B
$1.53M 0.53%
85,100
-51,400
-38% -$900K
RCL icon
79
Royal Caribbean
RCL
$82.1B
$1.53M 0.53%
+8,600
New +$1.39M
NOW icon
80
ServiceNow
NOW
$132B
$1.52M 0.52%
+8,500
New +$1.4M
BKNG icon
81
Booking.com
BKNG
$160B
$1.5M 0.52%
8,925
-10,000
-53% -$1.53M
CRNX icon
82
Crinetics Pharmaceuticals
CRNX
$8.95B
$1.48M 0.51%
28,911
-6,326
-18% -$326K
TKO icon
83
TKO Group
TKO
$14.2B
$1.45M 0.5%
+11,700
New +$1.34M
LEN icon
84
Lennar Class A
LEN
$21.1B
$1.44M 0.5%
+7,954
New +$1.33M
ARVN icon
85
Arvinas
ARVN
$588M
$1.43M 0.49%
58,001
+6,879
+13% +$180K
NFLX icon
86
Netflix
NFLX
$311B
$1.42M 0.49%
20,000
+2,000
+11% +$134K
INDV icon
87
Indivior Pharmaceuticals
INDV
$4.54B
$1.4M 0.48%
142,634
-36,202
-20% -$424K
GPCR icon
88
Structure Therapeutics
GPCR
$3.71B
$1.39M 0.48%
31,718
-3,410
-10% -$132K
ROIV icon
89
Roivant Sciences
ROIV
$25.5B
$1.33M 0.46%
115,326
-11,415
-9% -$130K
LLY icon
90
Eli Lilly
LLY
$1.08T
$1.33M 0.46%
1,500
– –
PM icon
91
Philip Morris
PM
$290B
$1.32M 0.46%
10,900
-600
-5% -$69.7K
UBER icon
92
Uber
UBER
$160B
$1.32M 0.46%
+17,600
New +$1.24M
TMUS icon
93
T-Mobile US
TMUS
$192B
$1.32M 0.46%
6,400
-5,500
-46% -$1.05M
ELV icon
94
Elevance Health
ELV
$84.7B
$1.3M 0.45%
+2,500
New +$1.34M
RXO icon
95
RXO
RXO
$3.54B
$1.29M 0.44%
+46,000
New +$1.3M
GEHC icon
96
GE HealthCare
GEHC
$32.9B
$1.24M 0.43%
13,200
-2,900
-18% -$243K
SWTX
97
DELISTED
SpringWorks Therapeutics
SWTX
$1.15M 0.4%
35,852
-15,135
-30% -$565K
TERN
98
DELISTED
Terns Pharmaceuticals
TERN
$1.09M 0.38%
130,966
-17,234
-12% -$142K
PDD icon
99
Pinduoduo
PDD
$129B
$1.09M 0.38%
8,078
+5,500
+213% +$676K
JANX icon
100
Janux Therapeutics
JANX
$1.01B
$1.07M 0.37%
23,472
+140
+0.6% +$6.09K
2 3
4
5 6

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q3 2024 Portfolio in Review

As of Q3 2024, HighVista Strategies held 174 positions worth $290M, up 5.9% from $274M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

HighVista Strategies's Q3 2024 filing shows 37 new, 46 increased, 48 reduced and 32 closed positions. Its largest new stake was Amgen: 10,101 shares worth $3.25M. The largest sale was Insmed, an estimated $6M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 44% a quarter earlier, followed by Technology and Consumer Discretionary.

  • HighVista Strategies's largest Q3 2024 buy was Amgen: 10,101 shares worth $3.25M.
  • HighVista Strategies added most to Protagonist Therapeutics in Q3 2024, an estimated $2.76M increase.
  • HighVista Strategies's biggest Q3 2024 reduction was Insmed, cutting an estimated $6M.
  • HighVista Strategies fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $4.02M.
  • HighVista Strategies's ten largest holdings make up 26% of its $290M portfolio in Q3 2024.
  • HighVista Strategies opened 37 new positions and closed 32 in Q3 2024.
  • HighVista Strategies's portfolio value rose 5.9% quarter-over-quarter to $290M.

Based on HighVista Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.